Unique ID issued by UMIN | UMIN000045542 |
---|---|
Receipt number | R000051999 |
Scientific Title | Prospective, observational study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease in a clinical practice covered by Japanese healthcare insurance |
Date of disclosure of the study information | 2021/09/22 |
Last modified on | 2021/09/22 16:02:40 |
Study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease
Study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease
Prospective, observational study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease in a clinical practice covered by Japanese healthcare insurance
Prospective, observational study on diagnosis and treatment of Mycobacterium avium complex pulmonary disease in a clinical practice covered by Japanese healthcare insurance
Japan |
Mycobacterium avium complex pulmonary disease
Medicine in general | Pneumology | Infectious disease |
Others
NO
To evaluate the relationship between the effects of multidrug chemotherapy for Mycobacterium avium complex pulmonary disease and long-term prognosis, and to search for useful prognostic predictors.
Safety,Efficacy
Exploratory
Not applicable
1)Relationship between the outcomes of multidrug chemotherapy and long-term survival prognosis
2)Search for useful prognostic predictors
Evaluation as prognostic factors the following:
1) clinical characteristics
2) chest radiographic findings
3) results of sputum smear-culture examinations for acid-fast bacteria, and serobar
4) results of blood examinations (especially serum antibodies against acid-fast bacteria)
Observational
18 | years-old | <= |
Not applicable |
Male and Female
1)Patients with Mycobacterium avium complex pulmonary disease met the criteria advocated by the American Thoracic Society 1997
2)Patients who can visit the hospital regularly for 5 years or more
3)Signed agreement to participate in the study
1)Patients known to be seropositive for human immunodeficiency virus
2)Judged inadequate to participate in the study by their physicians
41
1st name | Ryoji |
Middle name | |
Last name | Maekura |
National Hospital Organization Osaka Toneyama Medical Center
Department of Respiratory Medicine
560-8552
5-1-1 Toneyama, Toyonaka, Osaka, Japan.
06-6853-2001
mae.ryoji@gmail.com
1st name | Ryoji |
Middle name | |
Last name | Maekura |
Graduate School of Medical Safety Management, Jikei University of Health Care Sciences
Graduate school
532-0003
1-2-8 Miyahara, Yodogawa-ku, Osaka, Japan
06-6150-1336
mae.ryoji@gmail.com
National Hospital Organization Osaka Toneyama Medical Center
MHLW (Japan)
Japanese Governmental office
National Hospital Organization Osaka Toneyama Medical Center
5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan
06-6853-2001
410-chiken@mail.hosp.go.jp
NO
独立行政法人国立病院機構大阪刀根山医療センター(大阪府)
2021 | Year | 09 | Month | 22 | Day |
Unpublished
94
Completed
2004 | Year | 05 | Month | 10 | Day |
2004 | Year | 05 | Month | 21 | Day |
2004 | Year | 05 | Month | 21 | Day |
2020 | Year | 09 | Month | 30 | Day |
1)Relationship between the outcomes of multidrug chemotherapy and long-term survival prognosis
2)Search for useful prognostic predictors
Evaluation as prognostic factors the following:
1) clinical characteristics
2) chest radiographic findings
3) results of sputum smear-culture examinations for acid-fast bacteria
4) results of blood examinations (especially serum antibodies against acid-fast bacteria)
2021 | Year | 09 | Month | 22 | Day |
2021 | Year | 09 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051999